{"id":"NCT01001234","sponsor":"Organon and Co","briefTitle":"A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)","officialTitle":"A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11-30","primaryCompletion":"2011-04-21","completion":"2011-04-21","firstPosted":"2009-10-26","resultsPosted":"2012-05-08","lastUpdate":"2024-05-07"},"enrollment":1382,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine, Acute"],"interventions":[{"type":"DRUG","name":"rizatriptan","otherNames":["Maxalt","MK-0462"]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"rizatriptan","otherNames":["Maxalt","MK-0462"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Stage 1: rizatriptan","type":"EXPERIMENTAL"},{"label":"Stage 1: placebo","type":"PLACEBO_COMPARATOR"},{"label":"Stage 2: rizatriptan","type":"EXPERIMENTAL"},{"label":"Stage 2: placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This Clinical Trial evaluates the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents.","primaryOutcome":{"measure":"Pain Freedom at 2 Hours Post Dose in Participants Between 12 and 17 Years of Age","timeFrame":"2 hours post Stage 2 dose","effectByArm":[{"arm":"Rizatriptan","deltaMin":87,"sd":null},{"arm":"Placebo","deltaMin":63,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.025"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22711898"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":462},"commonTop":[]}}